PepGen (PEPG) reported a second-quarter net loss of $17.8 million, or $0.26 per basic and diluted share, for the three months ended June 30, 2026. Research and development expenses were $12.5 million, compared with $18.4 million in the same period of 2025.
The clinical-stage biotechnology company said cash, cash equivalents and marketable securities totaled $117.2 million as of June 30, 2026, which it expects to fund operations into the fourth quarter of 2027. PepGen also reported progress in its PGN-EDODM1 program for myotonic dystrophy type 1.
- Cash position: $117.2 million as of June 30, 2026.
- Net loss: $17.8 million for the second quarter, compared with $23.1 million a year earlier.
- EPS: Basic and diluted net loss per share was $0.26, compared with $0.70 in the 2025 period.
- Clinical update: The 10 mg/kg FREEDOM2-DM1 cohort is fully enrolled, with data expected in November.
- Pipeline timing: Results from the 12.5 mg/kg FREEDOM2-DM1 cohort are expected in the first half of 2027.
$PEPG Insider Trading Activity
$PEPG insiders have traded $PEPG stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $PEPG stock by insiders over the last 6 months:
- JAMES G MCARTHUR (President and CEO) has made 0 purchases and 2 sales selling 5,275 shares for an estimated $32,875.
- NOEL DONNELLY (Chief Financial Officer) has made 0 purchases and 2 sales selling 2,084 shares for an estimated $12,988.
- PAUL STRECK (EVP, Head of R&D) has made 0 purchases and 2 sales selling 1,879 shares for an estimated $11,708.
- KASRA KASRAIAN (Chief Technical Officer) sold 1,233 shares for an estimated $1,739
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$PEPG Hedge Fund Activity
We have seen 45 institutional investors add shares of $PEPG stock to their portfolio, and 45 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 2,208,444 shares (-97.1%) from their portfolio in Q1 2026, for an estimated $3,908,945
- BVF INC/IL removed 1,915,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $3,389,550
- MILLENNIUM MANAGEMENT LLC added 1,881,200 shares (+950.4%) to their portfolio in Q1 2026, for an estimated $3,329,724
- ADAR1 CAPITAL MANAGEMENT, LLC added 1,570,796 shares (+4263.6%) to their portfolio in Q1 2026, for an estimated $2,780,308
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,450,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,566,500
- PICTET ASSET MANAGEMENT HOLDING SA removed 1,306,783 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $2,352,209
- COMMODORE CAPITAL LP added 1,075,000 shares (+31.6%) to their portfolio in Q1 2026, for an estimated $1,902,750
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
